The Experts below are selected from a list of 345 Experts worldwide ranked by ideXlab platform

John A. Penner - One of the best experts on this subject based on the ideXlab platform.

  • Serologic markers of viral Hepatitis A, B, C, and D in patients with hemophilia.
    Journal of medical virology, 1993
    Co-Authors: Ashir Kumar, Roshni Kulkarni, Dennis L. Murray, Renuka Gera, A. B. Scott-emuakpor, Kathy Bosma, John A. Penner
    Abstract:

    Forty-one patients with hemophilia A were studied for the prevalence of serological markers for Hepatitis A, Hepatitis B, Hepatitis C (non-A and non-B Hepatitis), and Delta Hepatitis (Hepatitis D). Ten of 41 (24.4%) patients demonstrated Hepatitis A antibody and 31 of 41 (75.6%) patients had a serologic marker for previous Hepatitis B infection; four of these 31 patients (13%) also demonstrated antibody to Delta Agent (Hepatitis D). Thirty-seven of 41 (90.2%) patients demonstrated antibody for Hepatitis C. Nine of 31 (29%) patients with a Hepatitis B marker (no Hepatitis B vaccinees) were negative for anti-HBc but positive for anti-HBs; all of these nine patients were HIV antibody positive, although they had no overt immunodeficiency. Twenty-six of 41 (63.5%) patients were HIV antibody positive. Of HIV antibody positive patients, 27%, 88%, and 100% demonstrated evidence of a previous Hepatitis A, Hepatitis B, or Hepatitis C, respectively. Of HIV antibody negative patients; 20%, 53%, and 73% of the patients demonstrated evidence of a previous Hepatitis A, Hepatitis B, or Hepatitis C infections, respectively. The difference between HIV antibody positive and HIV antibody negative groups was not significant for Hepatitis A but was significant for Hepatitis B (P < 0.001) and Hepatitis C (P < .001). Of the 31 patients with a Hepatitis B serologic marker, all had antibody to Hepatitis C. Of 10 patients, without a Hepatitis B serologic marker, only 6 (60%) had antibody to Hepatitis C. Clinically, none of our patients demonstrated any evidence of liver disease; however, 10 patients reported a previous history of Hepatitis. These data suggest that patients with hemophilia in the United States, particularly those with HIV antibody, have high prevalence of Hepatitis B and C infections.

Ashir Kumar - One of the best experts on this subject based on the ideXlab platform.

  • Serologic markers of viral Hepatitis A, B, C, and D in patients with hemophilia.
    Journal of medical virology, 1993
    Co-Authors: Ashir Kumar, Roshni Kulkarni, Dennis L. Murray, Renuka Gera, A. B. Scott-emuakpor, Kathy Bosma, John A. Penner
    Abstract:

    Forty-one patients with hemophilia A were studied for the prevalence of serological markers for Hepatitis A, Hepatitis B, Hepatitis C (non-A and non-B Hepatitis), and Delta Hepatitis (Hepatitis D). Ten of 41 (24.4%) patients demonstrated Hepatitis A antibody and 31 of 41 (75.6%) patients had a serologic marker for previous Hepatitis B infection; four of these 31 patients (13%) also demonstrated antibody to Delta Agent (Hepatitis D). Thirty-seven of 41 (90.2%) patients demonstrated antibody for Hepatitis C. Nine of 31 (29%) patients with a Hepatitis B marker (no Hepatitis B vaccinees) were negative for anti-HBc but positive for anti-HBs; all of these nine patients were HIV antibody positive, although they had no overt immunodeficiency. Twenty-six of 41 (63.5%) patients were HIV antibody positive. Of HIV antibody positive patients, 27%, 88%, and 100% demonstrated evidence of a previous Hepatitis A, Hepatitis B, or Hepatitis C, respectively. Of HIV antibody negative patients; 20%, 53%, and 73% of the patients demonstrated evidence of a previous Hepatitis A, Hepatitis B, or Hepatitis C infections, respectively. The difference between HIV antibody positive and HIV antibody negative groups was not significant for Hepatitis A but was significant for Hepatitis B (P < 0.001) and Hepatitis C (P < .001). Of the 31 patients with a Hepatitis B serologic marker, all had antibody to Hepatitis C. Of 10 patients, without a Hepatitis B serologic marker, only 6 (60%) had antibody to Hepatitis C. Clinically, none of our patients demonstrated any evidence of liver disease; however, 10 patients reported a previous history of Hepatitis. These data suggest that patients with hemophilia in the United States, particularly those with HIV antibody, have high prevalence of Hepatitis B and C infections.

Roshni Kulkarni - One of the best experts on this subject based on the ideXlab platform.

  • Serologic markers of viral Hepatitis A, B, C, and D in patients with hemophilia.
    Journal of medical virology, 1993
    Co-Authors: Ashir Kumar, Roshni Kulkarni, Dennis L. Murray, Renuka Gera, A. B. Scott-emuakpor, Kathy Bosma, John A. Penner
    Abstract:

    Forty-one patients with hemophilia A were studied for the prevalence of serological markers for Hepatitis A, Hepatitis B, Hepatitis C (non-A and non-B Hepatitis), and Delta Hepatitis (Hepatitis D). Ten of 41 (24.4%) patients demonstrated Hepatitis A antibody and 31 of 41 (75.6%) patients had a serologic marker for previous Hepatitis B infection; four of these 31 patients (13%) also demonstrated antibody to Delta Agent (Hepatitis D). Thirty-seven of 41 (90.2%) patients demonstrated antibody for Hepatitis C. Nine of 31 (29%) patients with a Hepatitis B marker (no Hepatitis B vaccinees) were negative for anti-HBc but positive for anti-HBs; all of these nine patients were HIV antibody positive, although they had no overt immunodeficiency. Twenty-six of 41 (63.5%) patients were HIV antibody positive. Of HIV antibody positive patients, 27%, 88%, and 100% demonstrated evidence of a previous Hepatitis A, Hepatitis B, or Hepatitis C, respectively. Of HIV antibody negative patients; 20%, 53%, and 73% of the patients demonstrated evidence of a previous Hepatitis A, Hepatitis B, or Hepatitis C infections, respectively. The difference between HIV antibody positive and HIV antibody negative groups was not significant for Hepatitis A but was significant for Hepatitis B (P < 0.001) and Hepatitis C (P < .001). Of the 31 patients with a Hepatitis B serologic marker, all had antibody to Hepatitis C. Of 10 patients, without a Hepatitis B serologic marker, only 6 (60%) had antibody to Hepatitis C. Clinically, none of our patients demonstrated any evidence of liver disease; however, 10 patients reported a previous history of Hepatitis. These data suggest that patients with hemophilia in the United States, particularly those with HIV antibody, have high prevalence of Hepatitis B and C infections.

Dennis L. Murray - One of the best experts on this subject based on the ideXlab platform.

  • Serologic markers of viral Hepatitis A, B, C, and D in patients with hemophilia.
    Journal of medical virology, 1993
    Co-Authors: Ashir Kumar, Roshni Kulkarni, Dennis L. Murray, Renuka Gera, A. B. Scott-emuakpor, Kathy Bosma, John A. Penner
    Abstract:

    Forty-one patients with hemophilia A were studied for the prevalence of serological markers for Hepatitis A, Hepatitis B, Hepatitis C (non-A and non-B Hepatitis), and Delta Hepatitis (Hepatitis D). Ten of 41 (24.4%) patients demonstrated Hepatitis A antibody and 31 of 41 (75.6%) patients had a serologic marker for previous Hepatitis B infection; four of these 31 patients (13%) also demonstrated antibody to Delta Agent (Hepatitis D). Thirty-seven of 41 (90.2%) patients demonstrated antibody for Hepatitis C. Nine of 31 (29%) patients with a Hepatitis B marker (no Hepatitis B vaccinees) were negative for anti-HBc but positive for anti-HBs; all of these nine patients were HIV antibody positive, although they had no overt immunodeficiency. Twenty-six of 41 (63.5%) patients were HIV antibody positive. Of HIV antibody positive patients, 27%, 88%, and 100% demonstrated evidence of a previous Hepatitis A, Hepatitis B, or Hepatitis C, respectively. Of HIV antibody negative patients; 20%, 53%, and 73% of the patients demonstrated evidence of a previous Hepatitis A, Hepatitis B, or Hepatitis C infections, respectively. The difference between HIV antibody positive and HIV antibody negative groups was not significant for Hepatitis A but was significant for Hepatitis B (P < 0.001) and Hepatitis C (P < .001). Of the 31 patients with a Hepatitis B serologic marker, all had antibody to Hepatitis C. Of 10 patients, without a Hepatitis B serologic marker, only 6 (60%) had antibody to Hepatitis C. Clinically, none of our patients demonstrated any evidence of liver disease; however, 10 patients reported a previous history of Hepatitis. These data suggest that patients with hemophilia in the United States, particularly those with HIV antibody, have high prevalence of Hepatitis B and C infections.

Renuka Gera - One of the best experts on this subject based on the ideXlab platform.

  • Serologic markers of viral Hepatitis A, B, C, and D in patients with hemophilia.
    Journal of medical virology, 1993
    Co-Authors: Ashir Kumar, Roshni Kulkarni, Dennis L. Murray, Renuka Gera, A. B. Scott-emuakpor, Kathy Bosma, John A. Penner
    Abstract:

    Forty-one patients with hemophilia A were studied for the prevalence of serological markers for Hepatitis A, Hepatitis B, Hepatitis C (non-A and non-B Hepatitis), and Delta Hepatitis (Hepatitis D). Ten of 41 (24.4%) patients demonstrated Hepatitis A antibody and 31 of 41 (75.6%) patients had a serologic marker for previous Hepatitis B infection; four of these 31 patients (13%) also demonstrated antibody to Delta Agent (Hepatitis D). Thirty-seven of 41 (90.2%) patients demonstrated antibody for Hepatitis C. Nine of 31 (29%) patients with a Hepatitis B marker (no Hepatitis B vaccinees) were negative for anti-HBc but positive for anti-HBs; all of these nine patients were HIV antibody positive, although they had no overt immunodeficiency. Twenty-six of 41 (63.5%) patients were HIV antibody positive. Of HIV antibody positive patients, 27%, 88%, and 100% demonstrated evidence of a previous Hepatitis A, Hepatitis B, or Hepatitis C, respectively. Of HIV antibody negative patients; 20%, 53%, and 73% of the patients demonstrated evidence of a previous Hepatitis A, Hepatitis B, or Hepatitis C infections, respectively. The difference between HIV antibody positive and HIV antibody negative groups was not significant for Hepatitis A but was significant for Hepatitis B (P < 0.001) and Hepatitis C (P < .001). Of the 31 patients with a Hepatitis B serologic marker, all had antibody to Hepatitis C. Of 10 patients, without a Hepatitis B serologic marker, only 6 (60%) had antibody to Hepatitis C. Clinically, none of our patients demonstrated any evidence of liver disease; however, 10 patients reported a previous history of Hepatitis. These data suggest that patients with hemophilia in the United States, particularly those with HIV antibody, have high prevalence of Hepatitis B and C infections.